Prasetyani Margaretta A, de Mast Quirijn, Afeworki Robel, Kaisar Maria M M, Stefanie Difa, Sartono Erliyani, Supali Taniawati, van der Ven André J
Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Centre, Geert Groote Plein Zuid 8, 6500 HB, Nijmegen, The Netherlands.
Malar J. 2017 Jan 28;16(1):50. doi: 10.1186/s12936-017-1691-5.
Concern exists about the safety of iron supplementation given to individuals in malarious areas. The possible unfavourable impact of iron supplementation on malaria might be less when slow-release iron compounds are used instead of ferrous salts, because no toxic non-transferrin bound iron is formed. The aim of this study was to determine the effect of iron supplementation using the slow-release iron compound iron polymaltose (IPM) on the acquisition of malarial parasitaemia.
A randomized, placebo-controlled trial was performed in schoolchildren aged 5-18 years with mild or moderate anaemia on the Indonesian island Flores. Microscopic malaria-negative children were randomized to receive 8 weeks of IPM (6 mg elemental iron/kg/day) or placebo . The primary outcomes were the occurrence of microscopically detectable malarial parasitaemia at week 4, 8, 12 and 16 after start of treatment and the proportion of participants with real-time (RT) PCR positive malarial parasitaemia at week 16.
294 Children were assigned to the IPM group and 297 to the placebo group. Whereas IPM supplementation failed to increased haemoglobin or ferritin concentrations, the IPM group had a significantly higher rate of occurrence of microscopically detectable parasitaemia [hazard ratio 2.2, 95% C.I. 1.2-4.0; P = 0.01]. This higher rate was confined to iron-replete children. At the end of the study, 89% of the children in the IPM group had remained free from microscopically detectable parasitaemia vs 95% of children in the placebo group. The proportion of plasmodial RT-PCR positive children was similar in both groups at week 16 (IPM group 16.6% vs placebo group 14.3%; P = 0.47). When analysis was restricted to iron-replete children (serum ferritin ≥30 µg/l), there was a trend for a higher proportion being RT-PCR positive at week 16 in the IPM group compared with the placebo group (20 vs 13.3%; P = 0.07). Erythrocyte microcytosis was an independent risk factor for microscopically detectable malarial parasitaemia.
A short course of IPM should be used cautiously in anaemic children in malaria endemic areas, as it has limited efficacy in treating iron deficiency, while it increases the rate of microscopic malarial parasitaemia in those with replete iron stores. Trial registration ISRCTN 83091970. Registered 16 May 2012 (retrospectively registered).
疟疾流行地区人群补充铁剂的安全性受到关注。使用缓释铁化合物而非亚铁盐补充铁剂时,其对疟疾可能产生的不利影响或许会更小,因为不会形成有毒的非转铁蛋白结合铁。本研究旨在确定使用缓释铁化合物聚麦芽糖铁(IPM)补充铁剂对疟原虫血症感染的影响。
在印度尼西亚弗洛雷斯岛对5至18岁患有轻度或中度贫血的学童进行了一项随机、安慰剂对照试验。显微镜检查疟原虫阴性的儿童被随机分为接受8周的IPM(6毫克元素铁/千克/天)或安慰剂组。主要结局为治疗开始后第4、8、12和16周显微镜下可检测到的疟原虫血症的发生情况以及第16周实时(RT)PCR检测疟原虫血症呈阳性的参与者比例。
294名儿童被分配至IPM组,297名儿童被分配至安慰剂组。虽然补充IPM未能提高血红蛋白或铁蛋白浓度,但IPM组显微镜下可检测到的疟原虫血症发生率显著更高[风险比2.2,95%置信区间1.2 - 4.0;P = 0.01]。这一较高发生率仅限于铁储备充足的儿童。在研究结束时,IPM组89%的儿童显微镜下未检测到疟原虫血症,而安慰剂组为95%。第16周时,两组疟原虫RT - PCR阳性儿童的比例相似(IPM组为16.6%,安慰剂组为14.3%;P = 0.47)。当分析仅限于铁储备充足的儿童(血清铁蛋白≥30微克/升)时,与安慰剂组相比,IPM组在第16周时RT - PCR呈阳性的比例有升高趋势(分别为20%和13.3%;P = 0.07)。红细胞小红细胞症是显微镜下可检测到的疟原虫血症的独立危险因素。
在疟疾流行地区,贫血儿童应谨慎使用短期IPM疗程,因为其治疗缺铁的疗效有限,同时会增加铁储备充足儿童显微镜下疟原虫血症的发生率。试验注册号ISRCTN 83091970。于2012年5月16日注册(追溯注册)。